Invasive fungal infections are increasing in incidence and are associated with substantial
mortality. Improved diagnostics and the availability of new antifungals have revolutionized …

The need for better antifungal therapy is commonly accepted in view of the high mortality
rates associated with systemic infections, the low number of available antifungal classes …

Only two decades ago antibodies to fungi were thought to have little or no role in protection
against fungal diseases. However, subsequent research has provided convincing evidence …

Exosome-like vesicles containing virulence factors, enzymes, and antigens have recently
been characterized in fungal pathogens, such as Cryptococcus neoformans and …

Diseases caused by fungi can occur in healthy people, but immunocompromised patients
are the major risk group for invasive fungal infections. Cases of fungal resistance and the …

Despite increasing rates of invasive fungal infections being reported globally, only a single
antifungal drug has been approved during the last decade. Resistance, toxicity, drug …

Monoclonal antibodies (mAbs) are being used to prevent, detect, and treat a broad spectrum
of malignancies and infectious and autoimmune diseases. Over the past few years, the …

Antibody preparations have a long history of providing protection from infectious diseases.
Although antibodies remain the only natural host-derived defense mechanism capable of …

Non-mammalian models have been used to investigate fungal virulence. In this work we
have explored the use of Galleria mellonella as an infection model for the pathogenic …

The increasing incidence in systemic fungal infections in humans has increased focus for
the development of fungal vaccines and use of monoclonal antibodies. Invasive mycoses …